CN107530350A - 细胞坏死抑制剂及相关方法 - Google Patents

细胞坏死抑制剂及相关方法 Download PDF

Info

Publication number
CN107530350A
CN107530350A CN201580075297.0A CN201580075297A CN107530350A CN 107530350 A CN107530350 A CN 107530350A CN 201580075297 A CN201580075297 A CN 201580075297A CN 107530350 A CN107530350 A CN 107530350A
Authority
CN
China
Prior art keywords
compound
compounds
disease
following structure
dmso
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580075297.0A
Other languages
English (en)
Chinese (zh)
Inventor
J·袁
周义军
钱杉
马大伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Organic Chemistry of CAS
Ha Folishihui
Original Assignee
Shanghai Institute of Organic Chemistry of CAS
Ha Folishihui
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Organic Chemistry of CAS, Ha Folishihui filed Critical Shanghai Institute of Organic Chemistry of CAS
Publication of CN107530350A publication Critical patent/CN107530350A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201580075297.0A 2014-12-11 2015-12-11 细胞坏死抑制剂及相关方法 Pending CN107530350A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN201410764426 2014-12-11
CN2014107675953 2014-12-11
CN201410767595 2014-12-11
CN2014107644264 2014-12-11
US201562105475P 2015-01-20 2015-01-20
US201562105462P 2015-01-20 2015-01-20
US62/105,462 2015-01-20
US62/105,475 2015-01-20
PCT/US2015/065349 WO2016094846A1 (en) 2014-12-11 2015-12-11 Inhibitors of cellular necrosis and related methods

Publications (1)

Publication Number Publication Date
CN107530350A true CN107530350A (zh) 2018-01-02

Family

ID=56108283

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580075297.0A Pending CN107530350A (zh) 2014-12-11 2015-12-11 细胞坏死抑制剂及相关方法

Country Status (14)

Country Link
US (3) US9944628B2 (2)
EP (1) EP3229807A4 (2)
JP (1) JP2017538712A (2)
KR (1) KR20170123607A (2)
CN (1) CN107530350A (2)
AR (1) AR102981A1 (2)
AU (1) AU2015360291A1 (2)
CA (1) CA2970525A1 (2)
EA (1) EA201791289A1 (2)
IL (1) IL252827A0 (2)
MX (1) MX2017007607A (2)
SG (1) SG11201704764PA (2)
TW (1) TW201632516A (2)
WO (1) WO2016094846A1 (2)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020020119A1 (zh) * 2018-07-25 2020-01-30 浙江大学 Rip1抑制剂及其在医药中的用途
CN111978311A (zh) * 2019-05-21 2020-11-24 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
WO2022068075A1 (zh) * 2020-09-30 2022-04-07 浙江大学 化合物zju-37在制备肝脏疾病预防和/或治疗药物中的应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012513481A (ja) 2008-12-23 2012-06-14 プレジデント アンド フェロウズ オブ ハーバード カレッジ ネクロトーシスの小分子阻害剤
US9643977B2 (en) 2011-03-11 2017-05-09 President And Fellows Of Harvard College Necroptosis inhibitors and methods of use therefor
US20160024098A1 (en) 2013-03-15 2016-01-28 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
SG11201704764PA (en) 2014-12-11 2017-07-28 Harvard College Inhibitors of cellular necrosis and related methods
CN106619619A (zh) * 2017-01-06 2017-05-10 浙江大学 化合物hubin‑1在制备肝脏炎症性疾病预防和/或治疗药物中的用途
US20200062735A1 (en) 2017-02-27 2020-02-27 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
JP7140781B2 (ja) 2017-05-17 2022-09-21 デナリ セラピューティクス インコーポレイテッド 化合物、組成物および方法
CN108191835A (zh) * 2018-01-09 2018-06-22 中国药科大学 一类新型的含吡咯环和吲哚啉结构rip1激酶抑制剂及其用途
WO2020044206A1 (en) 2018-08-29 2020-03-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors for use in the treatment cancer
US20210147842A1 (en) * 2019-11-13 2021-05-20 President And Fellows Of Harvard College Methods and compositions for inhibiting necroptosis in neurovascular and/or neurodegenerative diseases or disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491743B2 (en) * 2003-08-29 2009-02-17 President And Fellows Of Harvard College Inhibitors of cellular necrosis
WO2013059791A2 (en) * 2011-10-21 2013-04-25 Massachusetts Eye And Ear Infirmary Methods and compositions for promoting axon regeneration and nerve function
WO2014152182A1 (en) * 2013-03-15 2014-09-25 President And Fellows Of Harvard College Deuterated heterocyclic inhibitors of necroptosis

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1044508A (en) * 1911-04-21 1912-11-19 Ajax Forge Company Railway-frog.
BE789948A (fr) 1971-10-13 1973-04-11 Sandoz Sa Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments
JPS5113156B2 (2) 1972-10-21 1976-04-26
US4016037A (en) 1975-10-15 1977-04-05 Ajinomoto Co., Inc. Method for producing L-amino acid
US4110536A (en) 1977-04-18 1978-08-29 Miles Laboratories, Inc. Derivatives of 5-(indol-3-yl)hydantoin
DE2728523C2 (de) 1977-06-23 1986-02-27 Schering AG, 1000 Berlin und 4709 Bergkamen 4-Methyl-1,2,3-thiadiazol-5-carbonsäure-(cyclohexylmethyl)-amid, Mittel mit herbizider und wachstumsregulatorischer Wirkung enthaltend diese Verbindung sowie Verfahren zu seiner Herstellung
JPS55136279A (en) * 1979-04-09 1980-10-23 Ajinomoto Co Inc Preparation of tryptophan hydantoin
JPS5810074B2 (ja) 1979-07-18 1983-02-24 味の素株式会社 新規微生物
US4332952A (en) 1980-07-28 1982-06-01 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
GB2080803B (en) 1980-07-28 1984-01-18 Pfizer Hypoglycemic 5-substituted oxazolidine-2,4-diones
EP0164247B1 (en) 1984-06-07 1989-01-11 Pfizer Limited Dihydropyridines
JPS6122081A (ja) 1984-07-10 1986-01-30 Mitsui Toatsu Chem Inc ヒダントイン化合物の製造法
US4684735A (en) 1985-07-01 1987-08-04 Stauffer Chemical Company Promotion of raney nickel hydrogenation catalyst
JPH0623148B2 (ja) 1985-09-05 1994-03-30 三井東圧化学株式会社 Ｎ−アセチル−ｄｌ−アミノ酸の製造方法
CA1292840C (en) 1985-09-26 1991-12-03 David Harry Hawke Sequencing of peptides
JPH0659227B2 (ja) 1985-11-08 1994-08-10 三井東圧化学株式会社 Ｄ−α−アミノ酸の製造方法
JPS6225990A (ja) 1986-07-19 1987-02-03 Kanegafuchi Chem Ind Co Ltd Ｄ−α−アミノ酸類の製造方法
US4705864A (en) 1986-11-10 1987-11-10 The Standard Oil Company Aryl oxime derivatives of hydantoins
US4911931A (en) 1987-08-03 1990-03-27 Baylink David J Pharmaceutical combination for treatment of bone-wasting diseases
JP2661111B2 (ja) 1988-03-09 1997-10-08 三菱化学株式会社 Ｄ−Ｎ−カルバミル−α−アミノ酸の製造法
US4868061A (en) 1988-05-19 1989-09-19 The Standard Oil Company Olefinic aryl oxime derivatives of hydantoins
IE62214B1 (en) 1988-05-25 1995-01-11 Warner Lambert Co Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents
JPH0219363A (ja) 1988-07-06 1990-01-23 Fujisawa Pharmaceut Co Ltd イミダゾリジン誘導体
WO1990004183A1 (en) 1988-10-07 1990-04-19 Commonwealth Scientific And Industrial Research Organisation Method for preparation of thiohydantoins and for protein sequence analysis
ATE94906T1 (de) 1989-01-02 1993-10-15 Ruetgerswerke Ag Verfahren zur herstellung von l-alphaaminos|uren.
JPH054910A (ja) 1990-07-31 1993-01-14 Nikka Chem Co Ltd 化粧料組成物
NZ239595A (en) 1990-08-31 1994-06-27 Warner Lambert Co Cholecystokinin antagonistic compounds ; pharmaceutical compositions and use thereof
JP2651755B2 (ja) 1991-03-01 1997-09-10 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料
NZ242065A (en) 1991-03-26 1996-06-25 Csl Ltd Delayed release implant having a degradable or rupturable polymeric coating
EP0533243B1 (en) 1991-09-16 1997-12-17 Merck & Co. Inc. Hydantoin and succinimide-substituted spiroindanylcamphorsulfonyl derivatives
US5693643A (en) 1991-09-16 1997-12-02 Merck & Co., Inc. Hydantoin and succinimide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists
CA2083891A1 (en) 1991-12-03 1993-06-04 Angus Murray Macleod Heterocyclic compounds, compositions containing them and their use in therapy
JP3163361B2 (ja) 1992-03-12 2001-05-08 味の素株式会社 ５−アルキルヒダントイン誘導体の製造法
US5574030A (en) 1992-07-14 1996-11-12 Nippon Chemiphar Co., Ltd. N-aminoalkyl-substituted nitrogen-containing five membered heterocyclic compounds
TW300895B (2) 1992-07-14 1997-03-21 Nippon Chemiphar Co
US5830854A (en) 1992-12-14 1998-11-03 Merck Sharp & Dohme, Limited Method of treating cystic fibrosis using a tachykinin receptor antagonist
US5338859A (en) 1993-02-12 1994-08-16 Hoechst Celanese Corporation Process for the production of calcium salts of hydantoic acids
EP0640594A1 (en) 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoin derivative as metalloprotease inhibitor
DE69513832T2 (de) 1994-09-08 2000-04-13 Eli Lilly And Co., Indianapolis Exzitatorische aminosäure-rezeptor-antagonisten
WO1996030393A1 (en) 1995-03-27 1996-10-03 Warner-Lambert Company A method for the synthesis of mixtures of compounds
US6166054A (en) 1995-03-31 2000-12-26 Nihon Nohyaku Co., Ltd. Agricultural and horticultural disease controller and a method for controlling the diseases
US5674734A (en) 1995-05-18 1997-10-07 President And Fellows Of Harvard College Cell death protein
DE19519717C1 (de) 1995-05-30 1996-08-22 Degussa Neuer Mikroorganismus, dessen Verwendung und Verfahren zur Herstellung von L-alpha-Aminosäuren
US6846839B1 (en) 1995-06-07 2005-01-25 Sugen, Inc. Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
US5962478A (en) 1995-09-19 1999-10-05 Margolin; Solomon B. Inhibition of tumor necrosis factor α
AU7457796A (en) 1995-10-23 1997-05-15 Tularik Inc. Rip: novel human protein involved in tumor necrosis factor signal transduction, and screening assays
KR20000010626A (ko) 1996-04-24 2000-02-25 한센 핀 베네드, 안네 제헤르 성장호르몬 방출성을 갖는 화합물
EP0930305B1 (en) 1996-09-30 2003-05-14 Nihon Nohyaku Co., Ltd. 1,2,3-thiadiazole derivatives and salts thereof, disease controlling agents for agricultural and horticultural use, and method for the use thereof
US5859190A (en) 1997-02-04 1999-01-12 Trega Biosciences, Inc. Combinatorial libraries of hydantoin and thiohydantoin derivatives, methods of making the libraries and compounds therein
ES2191286T3 (es) 1997-03-03 2003-09-01 Boehringer Ingelheim Pharma Moleculas pequeñas, utiles en el tratamiento de enfermedades inflamatorias.
IL126024A0 (en) 1998-03-19 1999-05-09 Yeda Res & Dev Modulators of the function of receptors of the tnf/ngf receptor family and other proteins
ATE238661T1 (de) 1998-07-30 2003-05-15 Nihon Nohyaku Co Ltd Fungizide zusammensetzung enthaltend ein 1,2,3- thiadiazolderivat sowie deren verwendung
DE59905623D1 (de) 1998-09-22 2003-06-26 Degussa Verfahren zur Herstellung von Imidazolidin-2,4-dionen
US6020198A (en) 1998-09-25 2000-02-01 Isis Pharmaceuticals Inc. Antisense modulation of RIP-1 expression
AU754989B2 (en) 1998-11-16 2002-11-28 Nippon Zoki Pharmaceutical Co., Ltd. A therapeutic agent for intractable vasculitis
WO2001007048A1 (en) 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
WO2001007044A1 (en) 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
WO2001028493A2 (en) 1999-10-15 2001-04-26 President And Fellows Of Harvard College Small molecule inhibitors of necrosis
US6756394B1 (en) 1999-10-15 2004-06-29 President And Fellow Of Harvard College Small molecule inhibitors of necrosis
US6706766B2 (en) 1999-12-13 2004-03-16 President And Fellows Of Harvard College Small molecules used to increase cell death
EP1275646A4 (en) 2000-03-30 2003-05-28 Sagami Chem Res INDOLYLPYRROL DERIVATIVES AND CELL DEATH INHIBITORS
US20020155172A1 (en) 2000-04-07 2002-10-24 Junying Yuan Methods and compounds for decreasing cell toxicity or death
GB0011071D0 (en) 2000-05-08 2000-06-28 Novartis Ag Organic compounds
US6846643B2 (en) 2000-08-14 2005-01-25 Boehringer Ingelheim Pharmaceuticals, Inc. Methods and molecules useful for identifying molecules that bind LFA-1 and for determining receptor occupancy
US20020064736A1 (en) 2000-09-27 2002-05-30 Fuji Photo Film Co., Ltd. Dye-forming coupler, silver halide photographic light-sensitive material, and method for producing an azomethine dye
JP2002145192A (ja) 2000-11-07 2002-05-22 Yamaha Motor Co Ltd 水上乗物の燃料タンク構造
JP4529338B2 (ja) 2001-03-08 2010-08-25 味の素株式会社 ヒダントイナーゼをコードするｄｎａ、ｎ−カルバミル−ｌ−アミノ酸ハイドロラーゼをコードするｄｎａ、組み換えｄｎａ、形質転換された細胞、タンパク質の製造方法および光学活性アミノ酸の製造方法
CA2460541A1 (en) 2001-09-14 2003-04-03 Helle Birk Olsen Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer
US20040019092A1 (en) 2001-11-14 2004-01-29 Daniel Berney Non-peptide somatostatin receptor ligands
MXPA04004830A (es) 2001-11-22 2004-07-30 Ono Pharmaceutical Co Compuestos derivados de piperidin-2-ona, y composiciones farmaceuticas que los contienen como ingredientes activos.
US6797708B2 (en) 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
JP3659224B2 (ja) 2001-12-26 2005-06-15 村田機械株式会社 インターネットファクシミリ装置
US7189856B2 (en) 2001-12-28 2007-03-13 Gideon Shapiro Non-peptide somatostatin receptor ligands
US7379820B2 (en) 2002-02-11 2008-05-27 Wyeth Solution structure of RIP DD and uses thereof
AU2003264211A1 (en) 2002-09-06 2004-03-29 Mount Sinai Hospital Methods for assaying protein-protein interactions
AU2003293124A1 (en) 2002-11-27 2004-06-23 Artesian Therapeutics, Inc. Heart failure gene determination and therapeutic screening
ATE378063T1 (de) 2002-12-20 2007-11-15 Novo Nordisk As Pharmazeutische zusammensetzungen mit insulin und insulin-hexamer-liganden
FR2850652B1 (fr) 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
GB0302671D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7320986B2 (en) 2003-03-07 2008-01-22 Abbott Labortories Fused tri and tetra-cyclic pyrazole kinase inhibitors
JP2007523842A (ja) 2003-03-11 2007-08-23 ノボ　ノルディスク　アクティーゼルスカブ 酸安定化されたインスリンを含有する薬学的製剤
WO2004080481A1 (en) 2003-03-13 2004-09-23 Novo Nordisk A/S Novel nph insulin preparations
JP4452914B2 (ja) 2003-09-08 2010-04-21 味の素株式会社 新規トランスポータタンパク質
US20080019909A1 (en) 2003-09-17 2008-01-24 Francis Ka-Ming Chan Modulation of Programmed Necrosis
DE10342839A1 (de) 2003-09-17 2005-04-28 Symrise Gmbh & Co Kg Thiohydantoine zur Aufhellung von Haut oder Haar
US6887993B1 (en) 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
WO2005080372A1 (en) 2004-02-19 2005-09-01 Bayer Healthcare Ag Dihydropyridinone derivatives
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
GB0410379D0 (en) 2004-05-11 2004-06-16 Univ Leicester Treatment of cancer
CA2573426C (en) 2004-07-30 2015-11-17 Exelixis, Inc. Pyrrole derivatives as pharmaceutical agents
JP2008530094A (ja) 2005-02-10 2008-08-07 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
WO2006103995A1 (ja) 2005-03-25 2006-10-05 Kaneka Corporation 光学活性α－アミノ酸誘導体の製造方法
RU2008110908A (ru) 2005-08-25 2009-09-27 Шеринг Корпорейшн (US) Производные имидазола в качестве функционально селективных агонистов альфа2с адренорецепторов
WO2007047146A2 (en) * 2005-10-11 2007-04-26 Intermune, Inc. Inhibitors of viral replication
EP1951706A1 (en) 2005-11-01 2008-08-06 Janssen Pharmaceutica N.V. Dihydroisoindolones as allosteric modulators of glucokinase
EP1968583A4 (en) 2005-12-20 2010-09-15 Harvard College COMPOUNDS, SCREENING AND TREATMENT PROCEDURES
AR056882A1 (es) 2006-02-01 2007-10-31 Bayer Cropscience Sa Derivados del fungicida n- cicloalquil- bencil- amida
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
JP2009542777A (ja) 2006-07-13 2009-12-03 ４エスツェー アクチェンゲゼルシャフト ベンゾピラノピラゾール
US20100087453A1 (en) 2006-10-10 2010-04-08 President And Fellows Of Harvard College Compounds, screens, and methods of treatment
HRP20120460T1 (hr) * 2007-06-06 2012-06-30 Dsm Sinochem Pharmaceuticals Netherlands B.V. Novi 5-supstituirani hidantoini
EP2192838A4 (en) 2007-08-15 2011-07-27 Harvard College HETEROCYCLIC NEKROPTOSIS HEMMER
JP2011517313A (ja) 2007-12-11 2011-06-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
JP2011512132A (ja) 2008-02-14 2011-04-21 エフ．ホフマン−ラ ロシュ アーゲー 骨髄毒性の予測方法
US20120061324A1 (en) * 2008-03-28 2012-03-15 Global Material Technologies, Inc. Element removal process and apparatus
US8304421B2 (en) 2008-09-30 2012-11-06 Vanderbilt University Indole compounds and their use as radiation sensitizing agents and chemotherapeutic agents
WO2010075290A1 (en) 2008-12-22 2010-07-01 President And Fellows Of Harvard College Unsaturated heterocyclic inhibitors of necroptosis
JP2012513481A (ja) 2008-12-23 2012-06-14 プレジデント アンド フェロウズ オブ ハーバード カレッジ ネクロトーシスの小分子阻害剤
JP2010202575A (ja) 2009-03-03 2010-09-16 Takeda Chem Ind Ltd 複素環化合物
DE102009002044A1 (de) 2009-03-31 2010-10-07 Evonik Degussa Gmbh Dipeptide als Futtermitteladditive
JP5332882B2 (ja) 2009-04-30 2013-11-06 豊田合成株式会社 半導体発光素子
JP2010275229A (ja) 2009-05-28 2010-12-09 Ikutoku Gakuen ヒダントイン誘導体
WO2011090738A2 (en) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
AR080234A1 (es) 2010-02-25 2012-03-21 Marrone Bio Innovations Inc Cepa bacteriana aislada del genero burkholderia y metabolitos pesticidas del mismo
US8987275B2 (en) 2010-03-16 2015-03-24 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
US20130018039A1 (en) 2010-03-31 2013-01-17 Bodmer Vera Q Imidazolyl-imidazoles as kinase inhibitors
WO2011133964A2 (en) 2010-04-23 2011-10-27 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
WO2012061045A2 (en) 2010-11-01 2012-05-10 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving retinal ganglion cells
US8664192B2 (en) 2011-03-07 2014-03-04 The Ohio State University Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer
WO2012154858A1 (en) 2011-05-09 2012-11-15 Whitehead Institute For Biomedical Research Chaperone interaction assays and uses thereof
CN102850252B (zh) 2011-06-30 2014-08-13 山东大学 一种3,5,5’-三取代乙内酰脲的制备方法
WO2013013826A1 (en) 2011-07-27 2013-01-31 Friedrich-Alexander-Universität Erlangen-Nürnberg Necroptosis inhibitors for the treatment of inflammatory diseases of the gastrointestinal tract
US9314328B2 (en) 2011-08-16 2016-04-19 W. L. Gore & Associates, Inc. Branched stent graft device and deployment
BR112014004386A2 (pt) 2011-08-27 2017-03-21 Marrone Bio Innovations Inc cepa bacteriana isolada do gênero burkholderia e formulações e usos como pesticida de seus metabólitos
US8492556B2 (en) 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US9353419B2 (en) 2012-05-04 2016-05-31 Novartis Ag Biomarkers for IAP inhibitor therapy
SG11201408280YA (en) 2012-06-26 2015-01-29 Biovalence Sdn Bhd Anticancer treatment
WO2014008167A2 (en) 2012-07-02 2014-01-09 Cell Assay Innovations, Inc. Cell-based assays for post-translational enzyme activity
JPWO2014126127A1 (ja) 2013-02-13 2017-02-02 国立大学法人北海道大学 ネクロプトーシス関連疾患の治療用医薬組成物及びその有効成分のスクリーニング方法
TWI637951B (zh) 2013-02-15 2018-10-11 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類
AU2014223344A1 (en) 2013-02-27 2015-10-01 Massachusetts Institute Of Technology T cell balance gene expression, compositions of matters and methods of use thereof
US20160024098A1 (en) 2013-03-15 2016-01-28 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
CA2907454C (en) 2013-03-21 2021-05-04 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
US20160051629A1 (en) 2013-04-15 2016-02-25 Yeda Research And Development Co. Ltd. Inhibition of rip kinases for treating lysosomal storage diseases
GB201316651D0 (en) 2013-09-19 2013-11-06 Univ Southampton Asthma
WO2015039705A1 (en) 2013-09-23 2015-03-26 Carl Zeiss Smt Gmbh Multilayer mirror
EP2857839A1 (en) 2013-10-01 2015-04-08 AIT Austrian Institute of Technology GmbH Breast cancer diagnostic method and means
WO2015077709A2 (en) 2013-11-22 2015-05-28 World Biotechnology LLC Method for harvesting organic compounds from genetically modified organisms
WO2015095449A1 (en) 2013-12-19 2015-06-25 Ptc Therapeutics, Inc. Methods for modulating the amount rna transcripts
EP3082820B1 (en) 2013-12-19 2022-07-20 PTC Therapeutics, Inc. Methods for modulating the amount of rna transcripts
US20150191511A1 (en) 2014-01-08 2015-07-09 World Biotechnology LLC Genetically Modified Organisms to Produce Organic Compounds
WO2015154197A1 (en) 2014-04-11 2015-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. Compositions and methods for glioblastoma treatment
US20170226514A1 (en) 2014-08-13 2017-08-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Prevention of tumour metastasis by inhibition of necroptosis
WO2016025129A1 (en) 2014-08-14 2016-02-18 Alhamadsheh Mamoun M Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
WO2016044777A1 (en) 2014-09-18 2016-03-24 Abbvie Inc. Hat inhibitors and methods for their use
EP3017825A1 (en) 2014-11-06 2016-05-11 Ludwig-Maximilians-Universität München An inhibitor of the RIPK1-dependent necrosis pathway and a pharmaceutical composition comprising the same
SG11201704764PA (en) 2014-12-11 2017-07-28 Harvard College Inhibitors of cellular necrosis and related methods
WO2016101885A1 (en) 2014-12-24 2016-06-30 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
EP3224245B1 (en) 2014-12-24 2018-09-12 National Institute Of Biological Sciences, Beijing Necrosis inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491743B2 (en) * 2003-08-29 2009-02-17 President And Fellows Of Harvard College Inhibitors of cellular necrosis
WO2013059791A2 (en) * 2011-10-21 2013-04-25 Massachusetts Eye And Ear Infirmary Methods and compositions for promoting axon regeneration and nerve function
WO2014152182A1 (en) * 2013-03-15 2014-09-25 President And Fellows Of Harvard College Deuterated heterocyclic inhibitors of necroptosis

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020020119A1 (zh) * 2018-07-25 2020-01-30 浙江大学 Rip1抑制剂及其在医药中的用途
CN110759895A (zh) * 2018-07-25 2020-02-07 浙江大学 新型rip1/rip3双靶点抑制剂及其在一药多靶疾病治疗中的用途
CN110759895B (zh) * 2018-07-25 2020-10-27 浙江大学 新型rip1/rip3双靶点抑制剂及其在一药多靶疾病治疗中的用途
CN112351979A (zh) * 2018-07-25 2021-02-09 浙江大学 Rip1抑制剂及其在医药中的用途
CN112351979B (zh) * 2018-07-25 2021-07-06 浙江大学 Rip1抑制剂及其在医药中的用途
CN111978311A (zh) * 2019-05-21 2020-11-24 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
CN111978311B (zh) * 2019-05-21 2024-05-31 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
WO2022068075A1 (zh) * 2020-09-30 2022-04-07 浙江大学 化合物zju-37在制备肝脏疾病预防和/或治疗药物中的应用

Also Published As

Publication number Publication date
US9499521B2 (en) 2016-11-22
AU2015360291A1 (en) 2017-07-13
TW201632516A (zh) 2016-09-16
EP3229807A4 (en) 2018-10-17
IL252827A0 (en) 2017-08-31
EP3229807A1 (en) 2017-10-18
US10508102B2 (en) 2019-12-17
SG11201704764PA (en) 2017-07-28
US20160168128A1 (en) 2016-06-16
KR20170123607A (ko) 2017-11-08
EA201791289A1 (ru) 2017-12-29
CA2970525A1 (en) 2016-06-16
JP2017538712A (ja) 2017-12-28
US20160304498A1 (en) 2016-10-20
US9944628B2 (en) 2018-04-17
WO2016094846A1 (en) 2016-06-16
US20190023690A1 (en) 2019-01-24
MX2017007607A (es) 2018-05-28
AR102981A1 (es) 2017-04-05

Similar Documents

Publication Publication Date Title
CN107530350A (zh) 细胞坏死抑制剂及相关方法
ZA200703596B (en) Thienopyridinone compounds and methods of treatment
CN101146776A (zh) 治疗炎性疾病的pgd2受体拮抗剂
JP2020520925A (ja) 化合物、組成物および方法
TW202019910A (zh) 組蛋白去乙醯酶雙環抑制劑
TWI809146B (zh) 組蛋白去乙醯酶雙環抑制劑
CA2883221A1 (en) Benzofurazan anti-amyloid compounds and methods
CN103649060A (zh) 方法
WO2009092284A1 (zh) 苯并环庚烯类衍生物、其制备方法及医药用途
WO2022125613A1 (en) Phosphonates as inhibitors of enpp1 and cdnp
CN112759545B (zh) 3-(二甲氨基甲基)哌啶-4-醇类衍生物及其制备方法和药物用途
CA2358586A1 (en) Tetrahydroindazole derivatives as ligands for gaba-a alpha 5 receptors
JP2004511486A (ja) デルタ−オピオイドアゴニストおよびアンタゴニストとしてのモルフィノイド誘導体
IE873436L (en) Condensed diazepinones
JPH0240381A (ja) 新規縮合ジアゼピノン類、それらの製造方法及びこれらの化合物を含有する医薬組成物
CN112759546B (zh) 3-(二甲氨基甲基)哌啶-4-醇衍生物及其制备方法和药物用途
KR20030036834A (ko) 5-페닐벤질아민 화합물, 그의 제법 및 그의 합성 중간체
WO2025042956A1 (en) Pde 7 modulator compounds
HK40070316B (zh) 用於治疗疾病的杂环化合物
WO2026092276A1 (zh) 用于抑制ptpn蛋白的化合物及其用途
WO2022119928A1 (en) Imidazole compounds as inhibitors of enpp1
NZ241635A (en) 10,11-dihydro-10,5-(iminomethano)-5h-dibenzo(a,d)cycloheptene derivatives and pharmaceutical compositions
HK1260375B (zh) 用於治疗疾病的杂环化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180102

WD01 Invention patent application deemed withdrawn after publication